E. R. Squibb Sons, Inc.

Bristol-myers Squibb Compnay

Adenosine Therapeutics, LLC

Ajit B Thakur

Nemichand B Jain

Dilbir S Bindra

Madhushree Yeshwant Gokhale

Cletus John Nunes

Divyakant S Desai

Thomas M Wong

Robert L Jerzewski

Hsun-Wen Hsu

James E Anderson

Lewis J Gryziewicz

A stable composition useful for myocardial perfusion imaging contains one or more 2-alkynyladenosine derivatives; and a solvent which is made up of water and hydroxypropyl-&#x3b2;-cyclodextrin.

Adenosine derivative formulations for medical imaging

Disclosed are salts and crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, at least one method of using at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide to treat cancer and/or other proliferative diseases, and processes to prepare crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof.

Pharmaceutical compositions comprising N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

Pharmaceutical compositions comprising N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-OXO-1,2-dihydropyridine-3-carboxamide

A rapid disintegrating and dispersing composition for thickening liquid waste into a thixotropic gel comprises a polymeric acrylic resin and a colloid-forming mixture of microcrystalline cellulose and sodium carboxymethylcellulose. Additional ingredients preferably used in making a tableted form of the composition include microcrystalline cellulose per se, polyvinylpolypyrrolidone, magnesium stearate and amorphous silica. The tablet is placed in suitable containment means such as a containment bag. The thixotropic properties of the composition enable the gelled waste to be restored to a liquid when small amounts of hand pressure are applied to the waste containment bag, thereby providing a convenient and simple means for disposal.

Rapidly disintegrating thickening composition

Shelf stable tablets containing fosinopril sodium are prepared by employing either sodium stearyl fumarate or hydrogenated vegetable oil as the lubricant. The tablets can contain conventional excipients such as fillers, binders, and disintegrants as well as an optional diuretic.

Fosinopril tablet formulations

In accordance with the present invention, a controlled release formulation is provided from which a drug, selected from the group consisting of angiotensin converting enzyme inhibitors and ascorbic acid, is released at a substantially controlled rate. The controlled release formulation of the invention is comprised of a reactive matrix of from about 5 to about 80 percent by weight of the drug in combination with from about 5 to about 70 percent by weight of poly[(1.fwdarw.4)-2-amino-2-deoxy-.beta.-D-glucose] (also referred to as chitosan herein). Further in accordance with the present invention there is provided a gel-like complex formed of the drug and the chitosan in environments ranging from neutral to acidic.

Controlled release formulation and method

Growing community of inventors

East Brunswick, NJ, United States of America

Ajit B Thakur